↓ Skip to main content

An Evaluation of MSDC-0160, a Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer's Disease.

Overview of attention for article published in Current Alzheimer Research, June 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 711)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news
61 news outlets
twitter
4 tweeters

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
An Evaluation of MSDC-0160, a Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer's Disease.
Published in
Current Alzheimer Research, June 2014
DOI 10.2174/1567205011666140616113406
Pubmed ID
Authors

R C Shah, D C Matthews, R D Andrews, A W Capuano, D A Fleischman, J T VanderLugt, J R Colca, Shah RC, Matthews DC, Andrews RD, Capuano AW, Fleischman DA, VanderLugt JT, Colca JR, Raj C Shah, Dawn C Matthews, Randolph D Andrews, Ana W Capuano, Debra A Fleischman, James T VanderLugt, Jerry R Colca

Abstract

Alzheimer's disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose metabolism measured by FDG-PET in regions that decline in AD.MSDC-0160 (150 mg once daily; N=16) compared to placebo (N=13) for 12 weeks did not result in a significant difference in glucose metabolism in pre-defined regions when referenced to the pons or whole brain. However, glucose metabolism referenced to cerebellum was maintained in MSDC-0160 treated participants while it significantly declined for placebo patients in anterior and posterior cingulate, and parietal, lateral temporal, medial temporal cortices. Voxel-based analyses showed additional differences in FDG-PET related to MSDC-0160 treatment. These exploratory results suggest central effects of MSDC-0160 and provide a basis for further investigation of mTOT modulating insulin sensitizers in AD patients.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 2%
Unknown 43 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 11 25%
Researcher 9 20%
Student > Master 8 18%
Student > Postgraduate 5 11%
Student > Bachelor 3 7%
Other 8 18%
Readers by discipline Count As %
Medicine and Dentistry 13 30%
Agricultural and Biological Sciences 9 20%
Unspecified 5 11%
Psychology 4 9%
Social Sciences 2 5%
Other 11 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 475. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 March 2017.
All research outputs
#16,276
of 12,751,656 outputs
Outputs from Current Alzheimer Research
#1
of 711 outputs
Outputs of similar age
#222
of 189,308 outputs
Outputs of similar age from Current Alzheimer Research
#1
of 8 outputs
Altmetric has tracked 12,751,656 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 711 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,308 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them